Cencora, Inc. (NYSE:COR) Shares Acquired by Ascent Group LLC

Ascent Group LLC boosted its holdings in Cencora, Inc. (NYSE:COR) by 245.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,833 shares of the company’s stock after acquiring an additional 4,855 shares during the quarter. Ascent Group LLC’s holdings in Cencora were worth $1,538,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Cetera Advisors LLC acquired a new stake in Cencora in the first quarter worth about $2,091,000. Mather Group LLC. lifted its stake in shares of Cencora by 11.5% in the 2nd quarter. Mather Group LLC. now owns 2,713 shares of the company’s stock worth $659,000 after acquiring an additional 279 shares during the period. Kingswood Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter worth approximately $655,000. CWM LLC boosted its holdings in shares of Cencora by 4.5% in the second quarter. CWM LLC now owns 11,898 shares of the company’s stock valued at $2,681,000 after acquiring an additional 509 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC increased its stake in shares of Cencora by 14.3% during the second quarter. Linden Thomas Advisory Services LLC now owns 6,655 shares of the company’s stock valued at $1,499,000 after acquiring an additional 832 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 93,018 shares of company stock valued at $22,478,942 in the last quarter. Company insiders own 15.80% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $250.05 on Wednesday. The business’s 50-day moving average is $235.84 and its 200-day moving average is $233.00. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market capitalization of $49.27 billion, a price-to-earnings ratio of 33.30, a P/E/G ratio of 1.66 and a beta of 0.45. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. Cencora’s dividend payout ratio is presently 29.29%.

Wall Street Analyst Weigh In

COR has been the subject of a number of research analyst reports. Robert W. Baird upped their price target on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. UBS Group increased their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Bank of America reiterated a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.